An Oncology Company Pioneering a Novel Therapy for Solid Tumors
Novocure™ is dedicated to the development of tumor treating fields therapy (NovoTTF™ Therapy), a new weapon for patients and physicians in the battle against cancer. NovoTTF Therapy is a novel anti-mitotic treatment that has been shown to slow or reverse tumor progression by inducing cell death in certain solid tumors. The company pioneered the concept that the electric properties of cells can be used as an effective target for an anti-neoplastic therapy.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Nov 9, 2020 | Post-IPO Debt | $150M | 1 | JP Morgan Chase | — | Detail |
Sep 28, 2009 | Series Unknown | — | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
JP Morgan Chase | Yes | Post-IPO Debt |
Pfizer | — | Series Unknown |